Rifampin for Biofilm Infections

Core Principles of Rifampin Use in Biofilm Infections

• The Infectious Diseases Society of America recommends rifampin as the agent of choice for treating staphylococcal biofilm-related implant infections, but it must always be combined with a companion antibiotic and should only be initiated after thorough surgical debridement when wounds are dry 1, 2
• The European Society of Clinical Microbiology and Infectious Diseases indicates that rifampin is specifically indicated for staphylococcal implant-related infections where the implant is retained or exchanged in one stage 1, 3

Mandatory Combination Therapy

• The American College of Cardiology and the Infectious Diseases Society of America state that rifampin must never be used as monotherapy due to extremely rapid emergence of resistance, and it should be combined with other antibiotics such as fluoroquinolones (ciprofloxacin or levofloxacin) for staphylococcal infections 1, 2, 3, 6
• The treatment algorithm for staphylococcal infections includes initial IV therapy (2-6 weeks) with oxacillin-susceptible or oxacillin-resistant antibiotics, followed by oral therapy with rifampin (300-450 mg twice daily) plus a companion drug such as ciprofloxacin or levofloxacin 1, 3, 6

Organism-Specific Considerations

• The Infectious Diseases Society of America recommends rifampin for staphylococcal biofilm infections, with proven efficacy against staphylococcal biofilms 1, 2
• The European Society of Clinical Microbiology and Infectious Diseases states that fluoroquinolones, not rifampin, are the biofilm-active agents for Gram-negative infections 1, 2, 4

Critical Pitfalls to Avoid

• The American College of Cardiology and the Infectious Diseases Society of America advise against starting rifampin before adequate debridement or while wounds are still draining, as this leads to selection of rifampin-resistant organisms, superinfection with resistant pathogens, and treatment failure 1, 5
• The Infectious Diseases Society of America warns that monotherapy with rifampin results in rapid resistance emergence and high failure rates, and even short periods of monotherapy are unacceptable 1, 3